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ABSTRACT
Objectives: To identify anthracycline-induced acute
(within 1 month) and early-onset chronic progressive
(within 1 year) cardiotoxicity in children younger than
16 years of age with childhood malignancies at a
tertiary care centre of Pakistan.
Design: Prospective cohort study.
Setting: Aga Khan University, Karachi, Pakistan.
Participants: 110 children (aged 1 month–16 years).
Intervention: Anthracycline (doxorubicin and/or
daunorubicin).
Outcome measurements: All children who received
anthracycline as chemotherapy and three
echocardiographic evaluations (baseline, 1 month and
1 year) between July 2010 and June 2012 were
prospectively analysed for cardiac dysfunction.
Statistical analysis including systolic and diastolic
functions at baseline, 1 month and 1 year was carried
out by repeated measures analysis of variance.
Results: Mean age was 74±44 months and 75
(68.2%) were males. Acute lymphoblastic leukaemia
was seen in 70 (64%) patients. Doxorubicin alone was
used in 59 (54%) and combination therapy was used
in 35 (32%). A cumulative dose of anthracycline
<300 mg/m2 was used in 95 (86%). Fifteen (14%)
children developed cardiac dysfunction within a month
and 28 (25%) children within a year. Of these 10/15
(66.6%) and 12/28 (43%) had isolated diastolic
dysfunction, respectively, while 5/15 (33.3%) and
16/28 (57%) had combined systolic and diastolic
dysfunction. Seven (6.4%) patients expired due to
severe cardiac dysfunction. Eight of 59 (13.5%)
children showed dose-related cardiotoxicity
(p=<0.001). Cardiotoxicity was also high when the
combination of doxorubicin and daunorubicin was
used (p=0.004).
Conclusions: Incidence of anthracycline-induced
cardiotoxicity is high. Long-term follow-up is essential
to diagnose its late manifestations.
INTRODUCTION
Anthracycline (doxorubicin, daunorubicin)
are potent but cardiotoxic chemotherapeutic
agents are essential for treating many child-
hood malignancies.1 Cardiotoxicity can be
acute (within a month of initiation of therapy),
early-onset chronic progressive (within a year
after therapy) and late-onset chronic
progressive (after a year of therapy).2–4 Cardiac
involvement may be seen as systolic and/or dia-
stolic dysfunction, cardiomyopathy, arrhythmias
and pericardial effusion (PE).1–3 Children with
cardiac dysfunction may be asymptomatic or
present with severe cardiac failure even with
isolated diastolic dysfunction.5 6 Cardiac
damage may begin with the ﬁrst dose of anthra-
cycline or appear at any dose as there is no
guaranteed safe dose limit. However, a higher
cumulative dosage and combination therapy
with different anthracycline derivatives are
important risk factors.7 8 Anthracycline-
induced diastolic dysfunction precedes systolic
impairment. Clinical trials data have shown
that anthracycline cardiotoxicity is associated
with the slowly progressive deterioration of
cardiac function, which may continue for years
after treatment cessation.9 10 Transthoracic
echocardiography is an important sensitive and
non-invasive tool for evaluation of left ventricu-
lar (LV) systolic and diastolic function.11–13
There is a dearth of literature reporting on
acute and/or long-term cardiotoxic adverse
effects associated with anthracycline use in
childhood malignancies from Pakistan. The
aim of this study was to identify cardiac dys-
function caused by the anthracycline and
factors related to it.
PATIENTS AND METHODS
This prospective cohort study was performed
during July 2010–June 2012 at the Aga Khan
University Hospital, Karachi, Pakistan. It com-
pared preanthracycline and postanthracycline
Strengths and limitations of this study
▪ First prospective cohort study on Anthracycline
induced cardiotoxicity from Pakistan.
▪ Repeated measures analysis of variance (r-ANOVA)
analysis applied at three different intervals to
detect acute and early onset cardiotoxicity.
▪ Single centre study. Poor follow-up was evident
in our population.
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echocardiographic evaluation in children aged 1 month–
16 years with various childhood malignancies. Children
with normal baseline echocardiography, who received
anthracycline (daunorubicin and/or doxorubicin) as a
part of their chemotherapy protocol and had the three
desired echocardiographic evaluations (prechemother-
apy 1-month and 1-year postchemotherapy), were
enrolled in the study. Children were excluded; (1) if they
were previously diagnosed with any structural heart
disease or cardiomyopathy, (2) if they had succumbed to
acute non-cardiac complications during their treatment
course, (3) if they had a relapse of cancer. Of 190 patients
enrolled in this study, 80 patients (42%) were excluded
because of poor follow-up, treatment migration, self-
treatment withdrawal. A total of 110 were available for
ﬁnal analysis (study ﬂow diagram). Sociodemographic
data were recorded and the type of cancer noted.
A written informed consent (approved by the hospital’s
ethical board) was obtained from parent or guardian by
the principle investigator at the time of enrolment in the
study. Anthracycline use, adverse events and possible
outcome was informed to the parents/guardians by
the treating paediatric oncologist. Demographic details,
type of malignancy, type and cumulative dose of anthracy-
cline and complications were noted. Anthracycline
cumulative dose with respect to body surface area was
calculated as mg/m2. None of our patients received
dexrazoxane during their management.
Echocardiographic analysis
GE vivid 7 Pro (General Electric Company, NYSE: GE,
UK) or Philips IE33 (Philips Medical Systems, Andover,
Massachusetts, USA) echocardiographic machines.
Real-time images were obtained from standard paraster-
nal, apical and subcostal projections. Transmitral inﬂow
velocity pattern was recorded from the apical four-
chamber view in accordance with the spectral Doppler
techniques described elsewhere.11 M-mode tracings were
taken from parasternal long axis view at the tips of
mitral valve leaﬂets perpendicular to the LV endocardial
surface and interventricular septum. Conscious sedation
was used when indicated.
A baseline echocardiography was carried out in all
patients as required in the management protocol.
Echocardiographic assessment of systolic and diastolic
LV function and PE was made. The mean of M-mode
measurements from four cardiac cycles with the
maximum diastolic diameters for each patient was used
for analysis. LV cavity and posterior wall were measured
in millimetre by the trailing edge-leading edge method.
LV diastolic diameter and posterior wall diameter was
measured at the point of maximum diastolic posterior
deﬂection of the posterior wall. LV shortening fraction
and ejection fraction were calculated by the formula
SF¼ðLVDDLVSDÞ=LVDD100ðnormalrange2938%Þ
EF¼ðLVDVLVSVÞ=LVDV100ðnormal.55%Þ
(SF, shortening fraction; EF, ejection fraction, LVDD, left
ventricular diastolic diameter; LVSD, left ventricular sys-
tolic diameter; LVDV, left ventricular diastolic volume;
LVSV, left ventricular systolic volume).
Transmitral inﬂow velocity in early diastole (E) and
during atrial contraction (A) was measured and E/A
ratio calculated. Pulsed Tissue Doppler Imaging was
used to record the velocity of myocardium during the
cardiac cycle. Peak early diastolic myocardial velocity
(E0) was measured at the lateral corner of the mitral
annulus to evaluate diastolic dysfunction, E/E0 ratio
assesses diastolic dysfunction.14–16 Myocardial perform-
ance index (MPI or Tei index) that incorporates systolic
and diastolic time intervals and expresses global ven-
tricular function was calculated using Doppler tracings
from mitral and aortic ﬂows. Isovolumic contraction
time (IVCT), ejection time (ET) and isovolumic relax-
ation time (IVRT) were measured by standard techni-
ques. In systolic dysfunction IVCT and IVRT will be
prolonged while ET will be shortened, whereas in dia-
stolic dysfunction IVRT will be prolonged.17 The higher
the Tei index, the more abnormal would be the ven-
tricular functions. Tei index was calculated as follows:
Tei index ¼ IVCTþ IVRT=ETðnormal range 0:4+ 0:09Þ
Echocardiographic evaluation for the acute and
early-onset chronic cardiotoxicity was performed at
three points in patient’s treatment course: baseline,
1 month and 1 year after chemotherapy.
The length of follow-up was measured from the ﬁrst
exposure to anthracycline. Preanthracycline echocardio-
graphic functions were compared with 1-month postan-
thracycline echocardiography for acute cardiotoxicity
and with 1-year postanthracycline echocardiography for
the early-onset cardiotoxicity. Additional echocardio-
graphic assessments were performed in case of cardiac
failure and managed accordingly.
Sample size
Sample size estimation was performed by using repeated
measures analysis of variance (r-ANOVA) design at three
different intervals. To detect a mean difference of 3–4%
units18 in ejection fraction, with SD of 8 from baseline
to 1 month (acute toxicity),19 using 90% power, with
95% CI and 5% level of signiﬁcance a maximum of 100
children were needed to detect the anthracycline-
induced cardiotoxicity. Owing to an expected 10%
dropout we inﬂate sample size to 110.
Statistical analysis
The statistical analysis was performed by using SPSS soft-
ware package (V.20.0, SPSS). Continuous variables (age,
weight, height, body surface area, haemodynamic para-
meters, cumulative anthracycline dose and echocardio-
graphic evaluation parameters) were presented in the
form of mean and SD. Categorical variables (gender,
type of childhood cancer, type of anthracycline and
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discharge disposition) were presented in frequency and
percentages. Statistical analysis across systolic and dia-
stolic dysfunction at baseline, 1 month and 1 year were
made by r-ANOVA using SPSS. A p value <0.05 was con-
sidered signiﬁcant.
RESULTS
Among the 110 children enrolled 75(68%) were males.
Mean age was 74±44 months (median; 62 months). The
demographic proﬁle of the study population is shown in
table 1. Haematological malignancies were predominant
(n=82; 75%, acute lymphoblastic leukaemia (ALL) in 70
and acute myeloid leukaemia (AML) in 12). Five chil-
dren had trisomy 21 (ALL in 3; AML in 2). Doxorubicin
alone or in combination with daunorubicin was used in
a majority of the children (n=94; 85%). Only 15 chil-
dren received a high dose of anthracycline (cumulative
dose >300 mg/m2). Follow-up echocardiography within
1 month revealed cardiac dysfunction in 15 (14%) chil-
dren, while 28 (25%) developed myocardial dysfunction
during their ﬁrst year postanthracycline chemotherapy
(ﬁgure 1).
Echocardiographic comparison of baseline myocardial
function with that at 1 month and 1 year using r-ANOVA
is shown in table 2. There was gradual and progressive
deterioration in all myocardial functional parameters
over time in children who received anthracycline.
Children with haematological malignancies developed
progressive cardiac dysfunction with time. Children with
AML were found to have two times higher risk of devel-
oping myocardial dysfunction at 1 year compared with
their baseline cardiac functions (table 3). Daunorubicin
use was associated with the highest incidence of cardiac
dysfunction at 1 year (10/16=63%) when compared with
doxorubicin alone or in combination. High cumulative
dose of doxorubicin, either alone or in combination
with daunorubicin, had signiﬁcant myocardial dysfunc-
tion (table 4).
DISCUSSION
Anthracycline use in childhood malignancies has
remarkably improved survival rates, increasing from 30%
in the 1960 to 70% in the present era.20 It is the key
component in many treatment strategies, but its cardio-
toxicity remains as an important concern. Incidence of
Table 1 Demographic features of children who received
anthracycline for their chemotherapy
Total number of patients n=110 (%)
Age (mean±SD) 74±44 months
Males 75 (68)
Body surface area (BSA)* 0.84±0.32
Type of malignancy
Haematological malignancies
ALL 70 (64)
AML 12 (11)
Non-haematological malignancies
Hodgkin+non-Hodgkin 19 (17)
Miscellaneous (Ewing sarcoma=4;
Wilms tumour=5)
9 (8)
Type of anthracycline
Doxorubicin 59 (53)
Combine doxorubicin and daunorubicin 35 (32)
Daunorubicin 16 (15)
Cumulative anthracycline dose (mg/m2)
<100 40 (36)
100–300 55 (50)
>300 15 (14)
Received radiation 24 (22)
Discharge disposition
Died 7 (6)
ALL, acute lymphoblastic leukaemia; AML, acute myeloid
leukaemia.
Figure 1 Study flow diagram highlighting key features of study cohort.
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anthracycline-induced acute cardiotoxicity ranges
between 3% and 21%, while late cardiotoxic effects vary
between 0% and 57%.21 22 Anthracycline-induced acute
cardiotoxicity in our study was 14%, which is a little high
compared with the data published earlier.3 23 Generally,
cumulative doses greater than 300–400 mg/m2 are asso-
ciated with the greatest risk for cardiac injury. In our
study, children receiving a cumulative dose >300 mg/m2
had shown signiﬁcant toxicity.
Anthracycline causes LV enlargement, both systolic
and diastolic diameters increase, resulting in decreased
fractioning shortening (FS) and EF. In our study base-
line FS changed signiﬁcantly after anthracyclines
(p=<0.001), which was similar to results published in the
past.22 In our study a baseline LVEF of 69±4% reduced
to 62.6±9.6% (p<0.001) at 1 year after completion of
anthracycline therapy. Anthracycline-induced cardiac
damage leads to deceased interventricular septal (IVS)
and LV posterior wall thickness (PWT), thereby increas-
ing after load and causing myocardial dysfunction.24 We
also found differences in PWT and IVS preanthracycline
and postanthracycline (p=<0.001).
Systolic and diastolic myocardial velocities correlate
well with systolic and diastolic ventricular functions.25 26
E, A and E0 velocities, E/A and E/E0 ratios, deceleration
time (DT) and MPI (Tei index) are good indicators of
diastolic dysfunction.14–16 Changes in EF occurs later in
the treatment course. The Tei index is more sensitive as
compared with EF and FS as it correlates well with inva-
sive measurements and has been validated in the assess-
ment of ventricular function, with higher values
suggesting poor prognosis. It can diagnose myocardial
dysfunction in children even after a low dose of anthra-
cyclines.27 In our study, within a year after completion of
therapy, there was a statically signiﬁcant change in dia-
stolic parameters like E velocity (p=<0.001), A velocity
(p=<0.001), E/A ratio (p=<0.001), E0 velocity
(p=<0.001) and E/E0 ratio (p=<0.001). The Tei index
and DT also showed signiﬁcant changes (p=<0.001).
These ﬁndings were consistent with the medical litera-
ture.28 29 Diastolic dysfunction has been reported to
predict future systolic dysfunction,30 and the same was
observed in our study as well. Of 15 children who devel-
oped cardiac dysfunction within a month, 10 (66.6%)
had isolated diastolic dysfunction, while at their 1-year
follow-up most of them had combined systolic and dia-
stolic dysfunction (16/28, 57%).
Long-term follow-up studies have demonstrated cardi-
otoxicity in up to 70% of children treated with anthracy-
cline.31 Younger patients are particularly susceptible to
Table 3 Relationship of anthracycline and cardiac dysfunction according to the type of malignancy
Malignancy
Cardiac dysfunction
p Value OR (95% CI)
Within a month
n (%)
Within a year
n (%)
ALL (n=70) 3 (4) 12 (17) 0.004 1.3 (1.0 to 1.8)
AML (n=12) 5 (42) 9 (75) 0.091 2.3 (1.1 to 4.7)
Hodgkin lymphoma (n=12) 3 (25) 2 (17) 0.045 0.1 (0.1 to 0.6)
Non-Hodgkin lymphoma (n=7) 2 (28) 2 (28) 1.000 4.0 (0.1 to 136.9)
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia.
Table 2 Echocardiographic parameters comparing baseline readings with within a month and within a year after the start of
anthracycline chemotherapy
Echocardiographic parameters Baseline readings Within a month Within a year p Value
EF (%) 69.9±4.3 67.3±5.3 62.6±9.6 <0.001
FS (%) 36.6±2.6 35.3±2.8 32.9±5.0 <0.001
PWT (mm) 6.7±1.3 5.8±1.1 5.4±1.1 <0.001
IVS (mm) 5.9±0.2 5.4±1.1 4.9±1.0 <0.001
LVEDD (mm) 34.5±5.6 35.8±5.4 37.3±5.8 <0.001
LVESD (mm) 22.0±4.2 23.4±4.4 25.3±5.4 <0.001
E (cm/s) 93.7±9.2 86.8±10.3 85.1±11.5 <0.001
A (cm/s) 58.9±6.5 63.5±7.5 64.6±9.1 <0.001
E/A ratio 1.6±1.8 1.38±0.21 1.3±.33 <0.001
E0 (cm/s) 14.1±2.4 12.2±2.3 11.1±2.5 <0.001
E/E0 ratio 6.7±1.05 7.17±1.1 8.1±2.6 <0.001
Tei index (MPI) 0.3±.05 0.4±.05 0.4±.07 <0.001
DT 164.3±15.3 171.6±19.8 174.7±28.9 <0.001
A, peak flow velocity during atrial contraction; DT, E deceleration time; E, early diastolic mitral peak flow velocity; E0, peak early diastolic
myocardial velocity; EF, ejection fraction; FS, fractioning shortening; IVS, interventricular wall thickness; LVEDD, left ventricular (LV) end
diastolic diameter; LVESD in mm, LV end systolic diameter; LVESD, LV end systolic diameter; PWT, LV posterior wall thickness; Tei index,
MPI=Myocardial performance index.
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anthracycline-induced cardiotoxicity. Incidence of
cardiac dysfunction found more in males and those
younger than 5 years in our study. Godoy et al,32 also
found that children younger than 4 years developed
more cardiotoxicity (p<0.01) in their study population.
Dysfunction is also related to the type of anthracycline
used. Both doxorubicin and daunorubicin are cardio-
toxic but doxorubicin is more cardiotoxic.33
Doxorubicin was used in 59/110 of our patients and
8/59 (13.5%) children showed cardiac dysfunction in
the acute phase. Their cumulative dose of doxorubicin
was signiﬁcantly higher as compared with those without
dysfunction, 279.4±184±.9 vs 103.6±69.4 mg/m2
(p=<0.001). Cardiotoxicity was also high when a combin-
ation of doxorubicin and daunorubicin was used
(p=0.004). In our study daunorubicin showed more
toxicity in the early-onset chronic progressive phase.
PE can develop as a complication of anthracycline or
radiation therapy, it may or may not be associated with
cardiac dysfunction. It can be an early and alarming sign
of cardiotoxicity suggestive of pericardial disease and
sometimes leads to haemodynamic instability.34
Nineteen patients developed PE in this study.
Long-term cardiac follow-up is essential for early
detection of cardiotoxicity because no dose of anthracy-
cline is safe in children.8 9 Cardiotoxicity may progress
years after discontinuation of therapy. Thirty years after
anthracycline treatment, survivors have 15 times more
chance of developing cardiac dysfunction than the
general population and mortality from cardiac causes is
eight times more.35 In our study, approximately 14%
developed dysfunction within a month that increased to
25% at 1 year after completion of therapy. The full
extent of the problem has yet to be addressed in many
asymptomatic patients after the completion of treat-
ment, emphasising the need for long-term follow-up.
In Pakistan multiple factors were related; non-
compliance in follow-up with cardiologist and oncologist
(in our study cardiac follow-up was seen in 58%).
Common factors found were, parents understanding
about disease, their educational status, ﬁnancial con-
straints, minimal government and non-government
agencies involvement and funding, remote area of resi-
dence far from treatment centres, paucity of treatment
centres, poor counselling regarding long-term follow-up,
lack of awareness among general practitioners regarding
acute and chronic cardiac complications. This empha-
sises the need for long–term cardiac follow-up for better
survival even in the asymptomatic patients.
A limitation of this study was that it involved a single
centre. Owing to the lack of availability none of our chil-
dren received cardioprotective agents such as dexrazox-
ane. Poor follow-up was evident in our study population
which led to the exclusion of 80 patients. There was a
high dropout rate; that is due to multiple factors afore-
mentioned and also in study ﬂow diagram.
CONCLUSION
The incidence of anthracycline-induced cardiac dysfunc-
tion is high. Risk factors include high cumulative dose,
doxorubicin alone or in combination with daunorubi-
cin. Regardless of the dose used, children treated with
anthracycline require a long-term follow-up to detect
late cardiotoxicity.
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Table 4 Types of anthracycline used alone or in combination and their relation to cardiac dysfunction
Anthracycline
Anthracycline cumulative dosage
p Value
Dysfunction
n (mg/m2, mean±SD)
No dysfunction
n (mg/m2, mean±SD)
Doxorubicin (n=59)
Within a month 8 (276±199) 51 (107±73) <0.001
Within a year 9 (279±185) 50 (104±69) <0.001
Daunorubicin (n=16)
Within a month 5 (315±114) 11 (273±93) 0.440
Within a year 10 (310±85) 6 (247±114) 0.224
Combination (n=35)
Within a month 2 (297±123) 33 (158±69) 0.011
Within a year 9 (228±81) 26 (144±64) 0.004
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